Eric A. Adams

This profile gathers the share dealings of Eric A. Adams in InMed Pharmaceuticals Inc., where the filings describe the role as chief executive. In total, 5 filings cover trades dated from 28 September 2021 to 20 February 2024.

The open-market record is one-sided, with 5 purchases worth €62k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2024 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €13k. On 2 out of 5 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 21 February 2024 with an open-market purchase (€14k) in InMed Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.